false
0001401914
0001401914
2026-11-10
2026-11-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 10, 2026
DARE BIOSCIENCE, INC
DARÉ
BIOSCIENCE, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-36395 |
|
20-4139823 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
3655
Nobel Drive, Suite 260
San
Diego, CA 92122
(Address
of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: (858) 926-7655
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
stock |
|
DARE |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item
5.07 |
Submission
of Matters to a Vote of Security Holders. |
A
special meeting of stockholders (the “Meeting”) of Daré Bioscience, Inc. (“Daré,” “we,”
“us,” or “our”) was held on November 10, 2026 and the following proposals were voted upon by our stockholders.
The proposals are described in detail in our definitive proxy statement for the Meeting filed with the U.S. Securities and Exchange Commission
on October 6, 2026. Below is a brief description of, and the final results of the votes for, each proposal.
Proposal
1: Our stockholders approved, in accordance with Nasdaq listing rules, the potential future issuance of shares of our common stock
upon the exercise of outstanding warrants by the votes set forth below.
| Votes
For |
|
Votes
Against |
Abstentions |
|
Broker
Non-Votes |
| 5,320,515 |
|
2,369,554 |
|
38,382 |
|
— |
Proposal
2: Our stockholders approved an adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of
Proposal 1 if there were not sufficient votes at the time of the Meeting to approve Proposal 1 by the votes set forth below. The adjournment
authorized by Proposal 2 was not necessary because there were sufficient votes to approve Proposal 1.
| Votes
For |
|
Votes
Against |
Abstentions |
|
Broker
Non-Votes |
| 5,364,004 |
|
2,311,408 |
|
53,039 |
|
— |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
DARÉ
BIOSCIENCE, INC. |
| |
|
| Dated:
November 12, 2026 |
By: |
/s/
Sabrina Martucci Johnson |
| |
Name: |
Sabrina
Martucci Johnson |
| |
Title: |
President
and Chief Executive Officer |
